公开(公告)号：US20220142944A1

公开(公告)日：2022-05-12

申请号：US17582273

申请日：2022-01-24

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe ARKIN ,  Marcel ZIGHELBOIM ,  Ori NOV ,  Ofer TOLEDANO ,  Karine NEIMANN ,  Hila HAKAK DJERBI

IPC: A61K31/05 ,  A61K47/18

Abstract: Disclosed are topical compositions and methods of treatment of a skin or mucosal disorder selected from palmoplantar psoriasis, hereditary palmoplantar keratoderma, acquired palmoplantar keratoderma, hydradenitis suppurativa, dermatitis, ichthyosis vulgaris, hereditary ichthyosis, acquired ichthyosis, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, Gorlin syndrome, nail psoriasis, flexural/inverse psoriasis, non-melanoma skin cancer, Cutaneous T-cell lymphoma and precancerous skin, mucosal and nail lesions, by once or twice daily topical administration to a subject of a composition comprising therapeutically effective amount of tapinarof.

公开(公告)号：US20220071924A1

公开(公告)日：2022-03-10

申请号：US17527582

申请日：2021-11-16

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe ARKIN ,  Marcel ZIGHELBOIM

IPC: A61K31/05 ,  A61P33/00 ,  A61K9/00

Abstract: The present invention relates to the treatment of an ocular inflammatory disease or an ocular degeneration disease by ophthalmic administration of a composition comprising tapinarof and optionally at least one additional active agent. Specifically, the ocular inflammatory disease is blepharitis. This invention provides a treatment of blepharitis and Demodex mites.

公开(公告)号：US20210346380A1

公开(公告)日：2021-11-11

申请号：US17352322

申请日：2021-06-20

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe ARKIN ,  Marcel ZIGHELBOIM ,  Ori NOV ,  Ofer TOLEDANO ,  Karine NEIMANN ,  Asher Cachlon

IPC: A61K31/517 ,  A61K9/00 ,  A61K45/06

Abstract: This invention relates to compositions and methods of treatment of skin or mucosal disorders by administration of compositions comprising at least one EGFR inhibitor, such as topical compositions comprising erlotinib. The compositions of this invention are useful for the treatment, prevention or amelioration of skin or mucosal disorders like psoriasis, palmoplantar psoriasis, acquired palmoplantar keratosis, eczema, ichtyosis vulgaris, non-melanoma skin cancer, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, pachyonychia congenita, hidradenitis suppurativa, Gorlin syndrome, prurigo nodularis and prurigo pigmentosa.

公开(公告)号：US20230390291A1

公开(公告)日：2023-12-07

申请号：US18453355

申请日：2023-08-22

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe ARKIN ,  Marcel ZIGHELBOIM ,  Ori NOV ,  Ofer TOLEDANO ,  Karine NEIMANN

IPC: A61K31/517 ,  A61P35/00 ,  A61K9/00

CPC classification number: A61K31/517 ,  A61P35/00 ,  A61K9/0014

Abstract: Provided herein compositions and methods of treatment of skin or mucosal disorders by administration of compositions comprising at least one EGFR inhibitor, such as topical compositions comprising erlotinib. The compositions of this invention are useful for the treatment, prevention or amelioration of skin or mucosal disorders like psoriasis, palmoplantar psoriasis, acquired palmoplantar keratosis, eczema, ichthyosis vulgaris, non-melanoma skin cancer, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, pachyonychia congenita, hidradenitis suppurativa, Gorlin syndrome, prurigo nodularis and prurigo pigmentosa.

公开(公告)号：US20220387349A1

公开(公告)日：2022-12-08

申请号：US17763231

申请日：2020-09-24

Applicant: Sol-Gel Technologies Ltd

Inventor： Moshe ARKIN ,  Marcel ZIGHELBOIM

IPC: A61K31/05 ,  A61K9/00 ,  A61K47/20 ,  A61K47/10 ,  A61K47/22 ,  A61K47/14 ,  A61K9/10 ,  A61K47/02 ,  A61K47/32 ,  A61K47/12 ,  A61K47/18 ,  A61K9/107 ,  A61K47/44 ,  A61K47/06 ,  A61K9/06 ,  A61K47/26 ,  A61K47/24

Abstract: Provided herein is a topical composition comprising tapinarof and methods of treatment of cutaneous adverse effects caused by oncological therapy with the tapinarof composition. The tapinarof compositions of this invention are useful for the treatment, prevention or amelioration of cutaneous and/or mucosal adverse effect caused by oncological therapy selected from chemotherapy, immunotherapy, radiation therapy, targeted therapy, hormone therapy and stem cell transplant therapy.

公开(公告)号：US20210346279A1

公开(公告)日：2021-11-11

申请号：US17313136

申请日：2021-05-06

Applicant: Sol-Gel Technologies Ltd.

Inventor： Marcel ZIGHELBOIM ,  Moshe ARKIN ,  Karine NEIMANN ,  Hila HAKAK DJERBI

IPC: A61K9/00 ,  A61K31/05 ,  A61K31/517 ,  A61P17/04 ,  A61K9/06

Abstract: The present invention, in some embodiments thereof, relates to a topical composition for use in treating, preventing, alleviating and/or ameliorating pruritus, wherein the composition comprises tapinarof and the pruritus is not associated with atopic dermatitis, psoriasis or any combination thereof.

公开(公告)号：US20230000786A1

公开(公告)日：2023-01-05

申请号：US17779151

申请日：2020-11-24

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe ARKIN ,  Marcel ZIGHELBOIM ,  Karine NEIMANN

IPC: A61K31/047 ,  A61K31/44 ,  A61K31/4035 ,  A61K31/69 ,  A61K31/203 ,  A61K45/06 ,  A61K9/00

Abstract: Provided herein is a topical combination composition comprising tapinarof, a PDE4 inhibitor and optionally at least one additional active agent selected from a retinoid, benzoyl peroxide (BPO), a Janus kinase inhibitor (JAK inhibitor), a corticosteroid of potency class 1-4, an acaricide and combinations thereof. The active agents in the composition of this invention are in encapsulated or non-encapsulated form, according to need. The above compositions are useful for the treatment, prevention or alleviation of a skin disorder selected from psoriasis, dermatitis, acne, rosacea, ichthyosis, scaling skin, imbalance of skin barrier and tinea and exhibit synergistic and/or additive effects allowing to reduce the active agents amounts in the combination compositions.

公开(公告)号：US20220331268A1

公开(公告)日：2022-10-20

申请号：US17763236

申请日：2020-09-24

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe ARKIN ,  Marcel ZIGHELBOIM

IPC: A61K31/05 ,  A61K9/00 ,  A61K31/496 ,  A61K31/235 ,  A61K31/203 ,  A61K31/192 ,  A61K31/4436 ,  A61K31/519 ,  A61K31/222 ,  A61K31/7048 ,  A61K31/167 ,  A61K9/48

Abstract: Provided herein is a topical combination composition comprising tapinarof, an additional AhR activator and optionally further comprising at least one additional active agent selected from a retinoid, benzoyl peroxide (BPO), a Janus kinase inhibitor (JAK inhibitor), a corticosteroid of potency class 1-4, an acaricide and combinations thereof. The active agents in the composition of this invention are in encapsulated or non-encapsulated form, according to need. The above compositions are useful for the treatment, prevention or alleviation of a skin disorder and exhibit synergistic and/or additive effects which allow reducing the amounts of the active agents in the compositions.

公开(公告)号：US20220287990A1

公开(公告)日：2022-09-15

申请号：US17629424

申请日：2020-07-23

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe ARKIN ,  Marcel ZIGHELBOIM ,  Ori NOV ,  Ofer TOLEDANO

IPC: A61K31/05 ,  A61K9/00 ,  A61K31/327 ,  A61K31/519 ,  A61K31/203 ,  A61K31/192 ,  A61K31/4436 ,  A61K31/4709 ,  A61K31/65 ,  A61K31/7056 ,  A61K31/7048 ,  A61K9/06

Abstract: Provided herein is a topical combination composition and a method of treatment of an inflammatory skin condition by administration of said composition comprising at least one Janus kinase inhibitor (JAK inhibitor) and at least one additional active agent elected from benzoyl peroxide (BPO), at least one retinoid, tapinarof, at least one antibiotic, at least one antiandrogen, at least one acaricide and combinations thereof and a carrier suitable for topical administration. The JAK inhibitor and the at least one additional active agent exhibit an additive or synergistic effect, allowing to reduce the amounts of active agents in the composition.

公开(公告)号：US20220062285A1

公开(公告)日：2022-03-03

申请号：US17521884

申请日：2021-11-09

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe ARKIN ,  Marcel ZIGHELBOIM ,  Ofra LEVY-HACHAM ,  Ori NOV

IPC: A61K31/517 ,  A61K45/06 ,  A61K9/00 ,  A61K9/06

Abstract: The present invention, in some embodiments, relates to a method of treatment, prevention or alleviation of Palmoplantar Keratoderma (PPK) or Olmsted syndrome in a patient in need thereof, comprising a debridement step followed by topical administration of a composition comprising at least one Epidermal Growth Factor Receptor (EGFR) inhibitor.